← back to search

Yajie Gao

First Affiliated Hospital of Xi'an Jiaotong University · CN
Area of research
Biomaterials · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Nanoparticle-Based Drug Delivery, Cardiac Imaging and Diagnostics, Lung Cancer Treatments and Mutations, and Lymphoma Diagnosis and Treatment.
h-index
15
citations
860
works
58
NIH funding
primary concept
email

Recent publications

Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study
EBioMedicine 2024cited by 9position: middledoi
744MO AdvanTIG-202: Phase II randomized, multicenter, open-label study of tislelizumab (TIS) with or without ociperlimab (OCI) in patients (pts) with previously treated recurrent/metastatic (R/M) cervical cancer (CC)
Annals of Oncology 2023cited by 7position: middledoi
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera <sup>®</sup> ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial
Hematological Oncology 2022cited by 9position: middledoi
Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma.
Journal of Clinical Oncology 2022cited by 2position: middledoi
Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study
Blood 2021cited by 1position: middledoi
Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
Frontiers in Oncology 2020cited by 2position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ivan Sinielnikov · Kyiv City Clinical Oncology Center1 papers (2023–2023)Hongxing Liu · Sinopec (China)1 papers (2023–2023) · 1 papers (2022–2022)D. Wang · Henan University1 papers (2023–2023)Lin Gui · University of Chicago1 papers (2022–2022)Junning Cao · Fudan University1 papers (2022–2022) · 1 papers (2023–2023)Yuankai Shi · Chinese Academy of Medical Sciences & Peking Union Medical College1 papers (2022–2022) · 1 papers (2022–2022) · 1 papers (2023–2023)Xin Mu · Jilin University1 papers (2023–2023)Xiang Li · Xinxiang Medical University1 papers (2022–2022)Zhen Wang · Hebei Normal University1 papers (2022–2022)Ting Wang · Anhui Mental Health Center1 papers (2023–2023)Weidong Wang · Sun Yat-sen University Cancer Center1 papers (2023–2023)Lei Zhang · Anhui Medical University1 papers (2022–2022)Xinliang Zhang · Nanjing University of Chinese Medicine1 papers (2023–2023)Kun Wang · Jiangsu University1 papers (2023–2023)Lin Wang · Shandong University1 papers (2023–2023)Qingyuan Zhang · Heilongjiang Institute of Technology1 papers (2022–2022)